Stay updated on Regeneron Press Releases

Sign up to get notified when there's something new on the Regeneron Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Regeneron Press Releases page

  1. Check
    yesterday
    Change Detected
    Summary
    Two new press releases were added (Q2 2026 financial results and Cemdisiran regulatory submissions). Two older items were removed (Dupixent EoE Phase 4 update and Q1 2026 results).
    Difference
    6%
    Check dated 2026-06-26T19:28:16.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    Navigation now shows 'Events & Presentations' and 'Stock Information' as dedicated items, consolidating related investor resources. This changes how users access press releases, events, and stock details from the page.
    Difference
    1%
    Check dated 2026-06-19T17:30:29.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The press releases list now shows fewer navigation cues because two pagination chevrons (» and ›) were removed. This may affect navigating to older releases, though it does not alter the content of the releases themselves.
    Difference
    0.6%
    Check dated 2026-06-12T11:32:57.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    Added a new press release item titled 'Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO' dated June 4, 2026 7:00 AM EDT. Removed the previously listed press release 'Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.' dated April 23, 2026 3:46 PM EDT.
    Difference
    2%
    Check dated 2026-06-05T08:26:24.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Two new press releases were added to the press releases page: Regeneron’s Ebola antibody was recommended by the World Health Organization for investigational use in response to a Bundibugyo ebolavirus outbreak, and Otarmeni (lunsotogene parvec) received EMA filing acceptance for genetic hearing loss. At the same time, two older items were removed from the listing: the FDA approval of Otarmeni-cwha for genetic hearing loss and the Dupixent approval for young children with CSU.
    Difference
    6%
    Check dated 2026-05-29T06:26:37.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The press releases list was updated to include several May 2026 announcements, and earlier April items were deleted, reflecting the latest company news on the investor site.
    Difference
    6%
    Check dated 2026-05-22T04:38:44.000Z thumbnail image

Stay in the know with updates to Regeneron Press Releases

Enter your email address, and we'll notify you when there's something new on the Regeneron Press Releases page.